Home
Drugs
Docetaxel

Docetaxel

Drug

Drug Profile

Docetaxel is a taxane chemotherapy medicine used for multiple cancers including breast, head and neck, stomach, prostate, and non-small-cell lung cancer. It is administered by slow IV infusion and may be used alone or in combination regimens. It is a prescription-only antineoplastic drug.

Drug Class: Taxane chemotherapy
Approval Status: Approved for medical use in 1995; prescription-only in major markets
Mechanism of Action: Disrupts normal microtubule function and thereby blocks cell division

Brand Names

Taxotere
Docecad
Docefrez

Indications

\Breast cancer\
\Head and neck cancer\
\Stomach cancer\
\Prostate cancer\
\Non-small-cell lung cancer\

Related News

FDA Approvals and Pipeline Expansion Drive Bladder Cancer Therapeutics Market Growth

Jun 23, 2026

The bladder cancer therapeutics market is expanding with recent FDA approvals including INLEXZO for NMIBC and a KEYTRUDA-Padvev combination for MIBC, while the NMIBC market reached approximately USD 3 billion in 2025 across seven major markets. Ferring reported record revenues exceeding €2.5 billion in 2025, driven by Adstiladrin as its second major growth driver. A robust pipeline of emerging therapies is expected to further transform the market through 2036.

New Research Advances Cancer Immunotherapy Through Clinical Data, Resistance Mechanisms, and Microbiome Insights

Jun 21, 2026

New clinical data for ANKTIVA immunotherapy in lung cancer, a study on EBV-driven resistance via ADAR1 RNA editing, and research on microbiome metabolites modulating immunotherapy response were presented at major conferences and in recent publications.

ESMO Guidelines Endorse Lutetium Therapy; New Data on PSMA Prediction, DOAC Safety

Jun 01, 2026

European guidelines now recommend lutetium-177 PSMA-617 for advanced prostate cancer, while a machine-learning model predicts treatment radiation dose. A study finds DOACs safe with modern prostate cancer drugs.

Ultra-Low-Dose Immunotherapy Shows Clinical Activity Across Multiple Trials

May 27, 2026

Three trials show ultra-low-dose checkpoint inhibitors retain efficacy with reduced toxicity and dramatically lower costs. DELII and Patil et al. trials tested low-dose nivolumab in solid tumors and HNSCC; NIVIPIT tested intratumoral low-dose ipilimumab in melanoma.

STAMPEDE Analysis Links Low On-Treatment PSA to Better Survival in Advanced Prostate Cancer

May 13, 2026

A post hoc STAMPEDE analysis found lower on-treatment PSA levels were strongly associated with improved long-term survival in advanced prostate cancer, but disease burden still affected outcomes.

Telix says ProstACT Global Phase 3 Part 1 met primary objectives

May 12, 2026

Telix said Part 1 of the ProstACT Global Phase 3 study met its primary objectives for TLX591-Tx in mCRPC. The company reported acceptable safety, no new safety signals and progression plans for Part 2.

Soft Tissue Sarcoma Pipeline Highlights Phase II and Late-Stage Programs

May 12, 2026

Soft tissue sarcoma pipeline activity includes 70+ companies and 75+ therapies. A phase II ADI-PEG 20 trial with gemcitabine and docetaxel was designed for sarcomas, while other 2026 studies span synovial sarcoma and unresectable advanced disease.

AstraZeneca nears pivotal data readout for sonesitatug vedotin in Claudin18.2 gastric cancer

Apr 24, 2026

AstraZeneca will report pivotal first-half data on sonesitatug vedotin in Claudin18.2 gastric cancer. The phase 3 Clarity-Gastric01 study is enrolling patients with ≥25% expression.

Zoldonrasib Shows Durable Responses in Previously Treated KRAS G12D-Mutant NSCLC

Apr 20, 2026

Updated phase I data showed zoldonrasib produced a 52% confirmed objective response rate and 93% disease control rate in previously treated KRAS G12D-mutant NSCLC. No grade 4 or higher treatment-related adverse events were observed at the recommended phase II dose.

Gotistobart shows early survival advantage over docetaxel in pretreated squamous NSCLC

Apr 17, 2026

Early results from stage I of the phase 3 PRESERVE-003 trial showed gotistobart improved overall survival versus docetaxel in previously treated metastatic squamous NSCLC. Objective response rate and duration of response also favored gotistobart, while progression-free survival did not differ significantly.

Related Clinical Trials

NCT ID	Title	Status	Phase
NCT07609251	A Clinical Study of SCTB41 Combined With Docetaxel in Patients With Previously Treated Locally Advanced or Metastatic Non-Small Cell Lung Cancer（Phase II Study Ongoing）	NOT_YET_RECRUITING	PHASE2
NCT07590934	Phase Ib/II Platform Study of Multiple Anti-Cancer Agents in Participants With Metastatic Prostate Cancer	NOT_YET_RECRUITING	PHASE1/PHASE2
NCT07566052	A Study to Compare Setidegrasib (ASP3082) With Docetaxel, in People With Non-small Cell Lung Cancer With a KRAS G12D Mutation	NOT_YET_RECRUITING	PHASE3
NCT07545044	A Study of JSKN003 Versus Trastuzumab in Combination With Pertuzumab and Docetaxel as First-Line Treatment for HER2-Positive Recurrent or Metastatic Breast Cancer	NOT_YET_RECRUITING	PHASE2
NCT07528274	Microwave Ablation Plus Tislelizumab and Docetaxel in Advanced NSCLC After First-Line Immunotherapy Failure	RECRUITING	PHASE2
NCT07518173	A Study of BL-M07D1 Combined With Pertuzumab Versus Docetaxel Plus Trastuzumab and Pertuzumab in Patients With First-line HER2-positive Recurrent or Metastatic Breast Cancer	NOT_YET_RECRUITING	PHASE3
NCT07518147	A Study Comparing BL-M05D1 With the Investigator's Choice of Treatment Regimen in Patients With Claudin (CLDN)18.2-Positive Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma (GC/GEJC) Who Have Received Prior First-Line Treatment	NOT_YET_RECRUITING	PHASE3
NCT07487896	A Study of YL201 Versus Investigator's Choice of Chemotherapy in Participants With Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma After Failure of First-Line Therapy	NOT_YET_RECRUITING	PHASE3
NCT07464327	A Phase III Study of HS-20093 Injection Combined With Adebrelimab Versus Docetaxel in Previously Treated Patients With Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer Without Actionable Genomic Alterations	NOT_YET_RECRUITING	PHASE3
NCT07459751	A Global Phase II/III Clinical Study to Evaluate the Efficacy and Safety of HLX43 Monotherapy or HLX43 in Combination With HLX07 Versus Docetaxel in Advanced or Metastatic Squamous Non-Small Cell Lung Cancer	RECRUITING	PHASE2/PHASE3